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1078–5884/00The Effects of Hydroxyethyl Starch Compared with
Gelofusine on Activated Endothelium and the Systemic
Inflammatory Response Following Aortic Aneurysm Repair
D. Rittoo,* P. Gosling, M.H. Simms, S.R.G. Smith and R.K. VohraDepartment of Vascular Surgery, Selly Oak Hospital, Raddlebarn Road, Selly Oak, Birmingham B29 6JD, UKObjective. To investigate the effect of HES, used as a plasma volume expander, on endothelial cell activation induced by
ischaemia-reperfusion in humans.
Material and Methods. Forty patients undergoing elective infrarenal aneurysm repair were randomised to receive either
gelatine or hydroxyethyl starch solution as plasma expanders. The anaesthetic technique was standardised. All patients
received the same crystalloid as per standard protocol. Urine samples and blood samples were collected at various times for
assessment of microalbuminuria and von Willebrand factor (vWf) and CRP.
Results. The peak C-reactive protein was significantly lower in the patients treated with HES than those treated with
gelofusine [142 mg/L (113,196 mg/L) vs 246 mg/L (189,291 mg/L) mg/L, P!0.01, Mann-Whitney test]. The peak ACR
was also significantly lower in the HES treated patients (9.3 mg/mmol vs 23.3 mg/mmol, P!0.05). The plasma level of vWf
was significantly higher in the gelofusine treated patients than those treated with HES [173.5 U/dl Vs 80.5 U/dl, P!0.001,
at 4 hr; 160 U/dl Vs 82.5 U/dl, P!0.001, at 8 hr; 191 U/dl Vs 100.5 U/dl, P!0.001, at 12 hr; 209 U/dl Vs 81.0 U/dl,
P!0.001, at 24 hr].
Conclusion. HES may damp down the systemic inflammatory response and reduce endothelial cell dysfunction.Keywords: Hydroxyethyl starch; Endothelium; von Willebrand factor antigen; Microalbuminuria; Ischaemiareperfusion;
Capillary permeability.The biochemical and cellular events that mediate
systemic inflammatory response cause activation of
the endothelial cells in various vascular beds. Once
activated these endothelial cells are able to participate
in neutrophil–endothelial interactions.1 This inter-
action is a needed defence mechanism, but may
precipitate organ dysfunction if unchecked.2 Cyto-
kines such as interleukin-6 and interleukin-8, as well
free radicals are some of the biochemical products
involved in the inflammatory response. Acute phase
proteins such as C-reactive protein, synthesised by the
liver in response to the systemic inflammation,
represent an index of the systemic inflammatory
response.
Activated endothelial cells secrete von Willebrand
factor (vWF) that serves a crucial role in mediating
platelet adhesion to sites of endothelial damage.3
Although it is secreted in small amounts constitutively,
vWF is also released by stimulus-induced exocytosis ofing author. D. Rittoo, MBChB, FRCS (Gen Surg),
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quantities of vWF in plasma can, therefore, be regarded
as a surrogate marker of endothelial cell activation,5 as
the contribution from platelets is very small.6
Besides the cellular metabolic changes, activated
endothelial cells also undergo ultrastructural changes.
Morphologically, activated endothelial cells are more
rounded with gaps appearing between adjacent
endothelial cells.7 The appearance of these gaps
makes it easier for large molecules such as albumin
to escape through the endothelial cell layer. This
increase in albumin filtration by the endothelial layer
can be quantified as an increase in the transcapillary
escape of albumin8 or as an increase in the urinary
excretion of albumin—microalbuminuria.9
It has previously been suggested recently that
hydroxyethyl starch (HES) can reduce the injurious
effect of ischaemia and reperfusion (I–R).10 In this
randomised study we investigated the effect of HES,
used as a plasma volume expander, on endothelial cell
activation and systemic inflammation induced by I-R in
humans.Eur J Vasc Endovasc Surg 30, 520–524 (2005)
doi:10.1016/j.ejvs.2005.04.046, available online at http://www.sciencedirect.com onved.
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Approval for the study was obtained from the local
research ethics committee. Forty patients scheduled
for elective abdominal aortic aneurysm surgery were
randomised to receive either hydroxyethyl starch (6%
eloHAES, Fresenius-Kabi, Milton Keynes, UK) or
gelatine solution (Gelofusine 4%, Braun, Sheffield,
UK) as colloids. The 6% eloHAES solution consists of
hexastarch molecules of average molecular weight
200,000 Da. The molecules are substituted at 1 and 6
and are slowly excreted via the kidneys after
hydrolysis by amylase. The size and the degree of
substitution give this molecule a different profile from
other HES molecules.11
Patients with pre-existing microalbuminuria,
defined as an overnight albumin excretion rates
of 20–200 mg/min, and a creatinine of greater than
150 mmol/l were excluded from the study. Patients
with occlusive disease were also excluded from the
study. Randomisation was by sealed envelopes that
were opened immediately prior to the start of
surgery. All patients were anaesthetised using a
standard technique of intravenous etomidate,
fentanyl and vecuronium and anaesthesia was
maintained with a mixture of nitrous oxide, oxygen
and isoflurane with endotracheal intubation. Intra-
operative and postoperative analgesia were
achieved via an epidural catheter placed after
induction of anaesthesia through which 2.5 mg of
morphine in 5 ml of 0.35% bupivacaine was
infused. Haemodynamic parameters were moni-
tored by a trans-oesophageal Doppler probe, an
indwelling triple lumen catheter in the internal
jugular vein for central venous pressure (CVP)
measurement, an indwelling radial artery line for
continuous systemic blood pressure reading and
for repeated arterial blood gas analysis. All
patients received the same crystalloid. All patients
received a litre of N-saline over 8 h before their
operation. Immediately after induction of anaes-
thesia, patients were infused with 15 ml/kg of
Hartman solution over 1 h followed by a mainten-
ance fluid of 3 ml/kg of Hartman solution per hour
during surgery. The study colloid was infused at
induction of anaesthesia. The volume of colloid
infused was based on various haemodynamic
parameters so as to achieve a stable heart rate,
CVP of 8–10 cm water, a steady mean arterial
pressure and a urine output of greater than
40 ml/h. When the intra-operative haemoglobin
fell below 10 g/dl, patients were transfused with
red blood cells. Blood collected by the cell saver
was infused in the normal way. Heparin wasadministered intravenously prior to aortic cross-
clamp at a dose of 40 units/kg. Whether a tube
graft or a bifurcated graft was used for the repair,
only one leg was re-perfused at a time to prevent
excessive haemodynamic changes. Blood and urine
samples were taken once haemodynamic control
was established.
Postoperatively, maintenance fluid replacement
was crystalloid at 2 ml/kg/h. The study colloid and
blood were infused as required to maintain a stable
heart rate, CVP of 8–10 cm water, a steady mean
arterial pressure and cardiac output. Blood was
transfused so as to maintain a haemoglobin of
10 g/dl. The volume of crystalloid infused could be
altered so as to maintain a urine output of greater than
40 ml/h postoperatively. Renal protection during
surgery was achieved by infusion of 0.5 g/kg of
mannitol given as an infusion of 10% solution prior
to infra renal aortic cross clamp. Urine samples were
collected at various time points for the determination
of urinary albumin and creatinine as follows: pre-
operatively (pre-op); before clamping of the abdomi-
nal aorta (Ind-Clp on); after clamp release (Clp off);
4-hourly thereafter for 12 h and daily for two post-
operative days. At these same time points, blood
samples were collected for measurement of plasma
vWF.Assessment of microalbuminuria
The urine samples were collected into sterile contain-
ers and kept at K70 8C until analysed. The analyses
were performed on the thawed specimen in batches.
The urine specimens were centrifuged to remove any
sediment that might interfere with the assay. The
microalbuminuria was determined by immunoturbi-
dimetry using the Cobas Mirae analyser. The results
were expressed as a ratio of albumin to creatinine
(ACR) in mg/mmol to allow for different urine flow
rates.Assay of vWF
Blood was collected into a vacutainer tube for von
Willebrand factor antigen measurement. The samples
were transported on ice prior to centrifugation.
Platelet poor plasma was obtained by centrifugation
of the blood sample at 3000g. The plasma was divided
into aliquots and stored at K70 8C until batch
analysed. The vWF concentrations were measured by
an enzyme-linked immunosorbent assay (Dako,
Copenhagen, Denmark). The coefficient of variation
was less than 10%.Eur J Vasc Endovasc Surg Vol 30, 11 2005
Table 1. Patients characteristics
HES nZ20 Gelofusine nZ20
Age/year 71.2 (6.7)* 73.8 (9.5)*
Male:female 14:6 16:4
Duration of operation (min) 140 (80–240)† 135 (70–180)†
Clamp time (min) 54 (30–120)† 51 (22–105)†
* Mean (SD).
† Median (range).
D. Rittoo et al.522Statistical analysis
The data were analysed using the Mann–Whitney test.
The median was expressed with their quartiles. Intra
group data were analysed using ANOVA. A P value of
less than 0.05 was accepted as being statistically
significant.Results
Both groups of patients were equally matched. The
ischaemia times were comparable (Table 1). The
volumes of colloid and crystalloid were significantly
different in the two groups of patients studied.
Patients treated with HES infusion required less
colloid [3000 ml (2500, 3437 ml) vs 3500 ml (3063,
4213 ml), P!0.01, Mann–Whitney test] and less
crystalloid [4650 ml (4500, 4788 ml) vs 4975 ml (4762,
5137 ml), P!0.01, Mann–Whitney test] than the
patients treated with gelofusine infusion. The volume
of cell saved blood and banked blood transfused were
not significantly different in the two groups of patients
[960 ml (721, 1280 ml) vs 960 ml (680, 1280 ml), PZns].
The haemoglobin on the first postoperative day was
comparable in both groups of patients [10.6 g/dl (10.0,
12.0) vs 11.9 g/dl (10.7, 12.2), PZns]. The platelet count
was significantly lower on the first postoperative day
in the HES treated patients than the gelofusine treated
patients [121!103 (101!103, 141!103) vs 147!103Fig. 1. Changes in ACR (median, interquartile range
Eur J Vasc Endovasc Surg Vol 30, 11 2005(128!103, 170!103), P!0.05, Mann–Whitney test].
The peak C-reactive protein was significantly lower in
the patients treated with HES than those treated with
gelofusine [142 mg/l (113, 196 mg/l) vs 246 mg/l (189,
291 mg/l), P!0.01, Mann–Whitney test].
The urinary excretion of albumin increased in both
groups of patients during surgery indicative of an
increase in capillary permeability. The excretion of
albumin in the urine peaked following reperfusion of
the extremities with release of the aortic cross clamp.
Twenty-four hours after reperfusion, the urinary
excretion of albumin returned to baseline levels.
There was a differential increase in the urinary
albumin: patients treated with gelofusine had a higher
excretion of albumin in the urine. The differences were
statistically significant immediately after release of the
aortic cross clamp (23.3 vs 9.3 mg/mmol, P!0.05) and
persisted for 4 h after reperfusion of the extremities
(8.6 vs 1.9 mg/mmol, P!0.01). There was a secondary
increase in the albumin excretion after 24 h in both
groups of patients studied (Fig. 1).
The plasma vWF level decreased following release
of the aortic cross clamp (Fig. 2). The plasma vWF
levels at clamp release were comparable in both
groups of patients (110 vs 96.5 U/dl, PZns). Thereafter
there was a significant increase in the plasma levels of
vWF in the group of patients treated with gelofusine
compared to the group of patients treated with HES
[173.5 vs 80.5 U/dl, P!0.001, at 4 h; 160 vs 82.5 U/dl,
P!0.001, at 8 h; 191 vs 100.5 U/dl, P%0.001, at 12 h;) in the perioperative period. *P!0.05, **P!0.01.
Fig. 2. Plasma vWF (median and interquartile range) in the perioperative period *P!0.01, **P!0.001.
The Effect of Hydroxyethyl Starch on the Endothelium 523209 vs 81.0 U/dl, P!0.0001, at 24 h]. During the first
24 h after reperfusion of the extremities, the plasma
level of vWF in the HES treated remained relatively
unchanged. On the first postoperative day, the plasma
level of vWF remained significantly lower in the HES
treated patients (259 vs 169 U/dl, P!0.0001).Discussion
The early increase in the urinary excretion of albumin
during surgery is consistent with previous obser-
vations that surgery induces an increase in the
systemic capillary permeability.9 The increase in
capillary permeability is highest after release of the
aortic cross clamp consistent with the reperfusion
injury of the ischaemic extremities. There was a
differential excretion of albumin in the urine in the
two groups of patients studied suggesting that there
was also a differential increase in capillary per-
meability (Fig. 1). This in turn is translated into the
observed differential requirements of both colloid and
crystalloid in these two groups of patients. The
transient increase in microvascular permeability and
its associated fluid shift has been shown to affect gas
exchange.12 It has previously been suggested that HES
can exert an effect on the leaky capillaries by sealing
the pores. Based on laboratory models it is suggested
that HES molecules of molecular weight ranging from
100 to 300 kDa may be more effective at plugging the
pores than HES molecules of larger molecular
weights.10 These experiments would suggest that the
effect of HES on activated endothelial cells is purely
biophysical. However, in trauma patients13 as in this
study the CRP levels in patients treated with HES were
lower. CRP is an acute phase protein synthesised in
response to pro-inflammatory mediators such as IL-6.
The plasma IL-6 has previously been shown to belower in patients treated with HES.14 HES may,
therefore, have anti-inflammatory properties.
Most of the plasma vWF is derived from endothelial
cells rather than platelet suggesting that vWF is a good
marker of endothelial dysfunction. Following reperfu-
sion of the extremities, the plasma level of vWF
decrease in both groups of patients. This decrease in
the plasma level of vWF probably reflects an increase
in the consumption of vWF by activated platelets
rather than a decrease in their release.15 The plasma
vWF was comparable in both groups of patients after
aortic clamp release consistent with a reperfusion
injury of equal magnitude inflicted by free radicals.
After the initial fall, the plasma vWF rose in the group
of patients treated with gelofusine indicating an
ongoing release of vWF by the activated endothelium.
In contrast, the plasma vWF in the patients treated
with HES did not change significantly after the initial
fall following reperfusion. This would suggest that
following the initial activation of the endothelium,
HES might be exerting a stabilising effect on the
endothelium, preventing further activation of endo-
thelial beds. Evidence in support of this hypothesis is
available from both in vivo16 an in vitro study showing
inhibition of endothelial cell activation by HES.17 This
inhibitory effect on the endothelium is translated into a
lesser increase in capillary permeability and a lower
CRP in the patients treated with HES.
vWF plays a vital role in platelet haemostasis. It
mediates platelet adhesion to sites of vascular damage
through interaction with platelet glycoprotein Ib. The
platelet count in this study decreased transiently in the
HES treated patients but remained above levels
required for normal haemostasis. The importance of
this decrease in the platelet count is not clear.
Treatment with HES has been associated with an
increased risk of bleeding through impairment of
vWF. The larger the HES molecule, the higher is the
risk of bleeding.18 Impairment in its synthesis,Eur J Vasc Endovasc Surg Vol 30, 11 2005
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elimination has been theorised.19 Whether the persist-
ent rise in plasma vWF is secondary to poor plasma
clearance or sustained release from the activated
endothelial cells could not fully be addressed in this
study. As the plasma half-life of vWF is longer than the
time intervals the blood samples were taken, the lower
plasma concentration of vWF in the HES treated group
could not satisfactorily be explained by the plasma
clearance alone. Measurement of the propeptide,
released in equimolar concentration but with a shorter
half-life than the mature vWF,20 might provide more
information on the time scale of endothelial
dysfunction.
The best way of assessing endothelial function is
uncertain. The possible advantage of using endothelial
cell function surrogates is that they reflect the net
effects of a number of different molecular pathways. It
appears that the effects of HES on the endothelium can
be a double-edged sword that on one hand prevents
excessive activation of the inflammatory process and
on the other can interfere with haemostasis. This study
shows that when used in the right pathophysiological
states such as in abdominal aortic aneurysm repair,
volume expansion with HES can confer significant
benefits in terms of damping down the inflammatory
cascade and endothelial cell dysfunction.References
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